Yanmiao Huo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yanmiao Huo has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Hong Li
CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
14 shared publications - Jianyu Yang
Shanghai Jiao Tong University 1 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine Shanghai, China
14 shared publications - Junfeng Zhang
Shanghai Jiao Tong University 1 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine Shanghai, China
14 shared publications - Lingye Tao
Shanghai Jiao Tong University 1 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine Shanghai, China
14 shared publications - Linli Yao
Shanghai Jiao Tong University 3 State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine Shanghai, China
14 shared publications - Minwei Yang
Shanghai Jiao Tong University 1 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine Shanghai, China
14 shared publications
Latest Publications
- 20 June 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (30) , 1-19
A cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling, ribosome biogenesis and growth in pancreatic ductal adenocarcinoma
Cellular adaptive volume regulation is essential for maintaining metabolic homeostasis and supporting survival, yet its role in desmoplastic pancreatic ductal adenocarcinoma (PDAC) remains incompletely understood. Through comprehensive bioinformatic and functional studies, we identified LRRC8A, the core subunit of volume-regulated anion channels (VRAC), as a central regulator linking volume homeostasis to PDAC progression. Beyond its established role in osmotic stress responses, genetic silencing or pharmacological inhibition of LRRC8A revealed its critical function in proliferation-associated volumetric expansion during S-phase. Functional validation through in vitro proliferation assays, in vivo xenograft models, and patient-derived pancreatic cancer organoids (PDO) demonstrated that LRRC8A critically drives PDAC progression. Mechanistically, LRRC8A coordinates plasma membrane dynamics, cortical cytoskeletal organization, membrane-delimited oncogenic signaling (KRAS/EGFR), and nucleolar ribosome biogenesis to support volumetric expansion during S phase. Co-immunoprecipitation coupled with mass spectrometry identified that LRRC8A forms complexes with Caveolin 1 (CAV1). Disruption of LRRC8A leads to decreased CAV1 protein levels, impaired activation of KRAS and EGFR oncogenic signaling, and suppressed ribosome biogenesis and global protein synthesis. Reciprocally, CAV1 knockdown or cholesterol depletion using lovastatin destabilized LRRC8A in plasma membrane, resulting in reduced cortical F-actin organization, oncogenic signaling and biosynthetic activity, indicating that LRRC8A and CAV1 are mutually stabilized and depend on cholesterol-rich membrane microdomains for proper integration and function. Furthermore, disruption of LRRC8A-CAV1 axis through LRRC8A inhibition or cholesterol depletion potently suppressed PDO growth in vitro. Collectively, our work establishes the LRRC8A-CAV1 complex as a key coordinator of biosynthetic expansion and a promising therapeutic target in pancreatic cancer.
- 20 June 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (30) , 1-19
A cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling, ribosome biogenesis and growth in pancreatic ductal adenocarcinoma
Cellular adaptive volume regulation is essential for maintaining metabolic homeostasis and supporting survival, yet its role in desmoplastic pancreatic ductal adenocarcinoma (PDAC) remains incompletely understood. Through comprehensive bioinformatic and functional studies, we identified LRRC8A, the core subunit of volume-regulated anion channels (VRAC), as a central regulator linking volume homeostasis to PDAC progression. Beyond its established role in osmotic stress responses, genetic silencing or pharmacological inhibition of LRRC8A revealed its critical function in proliferation-associated volumetric expansion during S-phase. Functional validation through in vitro proliferation assays, in vivo xenograft models, and patient-derived pancreatic cancer organoids (PDO) demonstrated that LRRC8A critically drives PDAC progression. Mechanistically, LRRC8A coordinates plasma membrane dynamics, cortical cytoskeletal organization, membrane-delimited oncogenic signaling (KRAS/EGFR), and nucleolar ribosome biogenesis to support volumetric expansion during S phase. Co-immunoprecipitation coupled with mass spectrometry identified that LRRC8A forms complexes with Caveolin 1 (CAV1). Disruption of LRRC8A leads to decreased CAV1 protein levels, impaired activation of KRAS and EGFR oncogenic signaling, and suppressed ribosome biogenesis and global protein synthesis. Reciprocally, CAV1 knockdown or cholesterol depletion using lovastatin destabilized LRRC8A in plasma membrane, resulting in reduced cortical F-actin organization, oncogenic signaling and biosynthetic activity, indicating that LRRC8A and CAV1 are mutually stabilized and depend on cholesterol-rich membrane microdomains for proper integration and function. Furthermore, disruption of LRRC8A-CAV1 axis through LRRC8A inhibition or cholesterol depletion potently suppressed PDO growth in vitro. Collectively, our work establishes the LRRC8A-CAV1 complex as a key coordinator of biosynthetic expansion and a promising therapeutic target in pancreatic cancer.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S3. Analysis of bulk RNA-seq data on metastatic tumor tissues of anti-PD1 monotherapy, anti-LAG3 monotherapy and anti-PD1 plus anti-LAG3 combined therapy.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S3. Analysis of bulk RNA-seq data on metastatic tumor tissues of anti-PD1 monotherapy, anti-LAG3 monotherapy and anti-PD1 plus anti-LAG3 combined therapy.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Signature genes of M1 and M2 macrophages derived from PMID: 33545035.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Signature genes of M1 and M2 macrophages derived from PMID: 33545035.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Signature genes of all ductal subclusters.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Signature genes of all ductal subclusters.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
GSEA results for all ductal subclusters using genesets collected from published articles.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
GSEA results for all ductal subclusters using genesets collected from published articles.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Cell markers for celltype annotation.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Cell markers for celltype annotation.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Clinical information of patients with metastatic PDAC.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Clinical information of patients with metastatic PDAC.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
GSEA results for all ductal subclusters using Gene Ontology (GO) terms.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
GSEA results for all ductal subclusters using Gene Ontology (GO) terms.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S4. Association between H2AFZ expression and genomic mutations in PDAC.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S4. Association between H2AFZ expression and genomic mutations in PDAC.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S2. Cellular compositions of myeloid and T cell subclusters between hepatic metastases and healthy livers.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S2. Cellular compositions of myeloid and T cell subclusters between hepatic metastases and healthy livers.